Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Enanta Pharmaceuticals	Phibro Animal Health	Arcturus Therapeutics	Akero Therapeutics	ESSA Pharma
Symbol	NASDAQ:ENTA	NASDAQ:PAHC	NASDAQ:ARCT	NASDAQ:AKRO	NASDAQ:EPIX
Price Information
Current Price	$48.20	$27.97	$30.82	$27.16	$29.75
52 Week Range	Hold	Sell	Hold	Buy	Buy
MarketRank™
Overall Score	1.4	1.6	1.6	1.7	1.4
Analysis Score	3.1	0.5	3.1	4.5	1.5
Community Score	2.3	2.2	2.6	2.4	3.1
Dividend Score	0.0	2.5	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	1.7	2.5
Earnings & Valuation Score	0.0	1.3	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Hold	Sell	Hold	Buy	Buy
Consensus Price Target	$65.29	$22.00	$68.58	$57.29	$28.80
% Upside from Price Target	35.45% upside	-21.34% downside	122.53% upside	110.92% upside	-3.19% downside
Trade Information
Market Cap	$999.85 million	$1.14 billion	$756.70 million	$968.00 million	$993.13 million
Beta	0.54	0.46	3.01	0.58	1.96
Average Volume	140,581	138,304	1,055,610	274,728	331,182
Sales & Book Value
Annual Revenue	$122.47 million	$800.40 million	$20.79 million	N/A	N/A
Price / Sales	7.95	1.42	39.02	N/A	N/A
Cashflow	N/A	$2.52 per share	N/A	N/A	N/A
Price / Cash	N/A	11.10	N/A	N/A	N/A
Book Value	$22.70 per share	$4.65 per share	$1.70 per share	$4.51 per share	$2.47 per share
Price / Book	2.12	6.02	18.13	N/A	N/A
Profitability
Net Income	$-36,170,000.00	$33.55 million	$-25,990,000.00	$-43,760,000.00	$-23,440,000.00
EPS	($0.89)	$1.08	($2.15)	($2.90)	($1.04)
Trailing P/E Ratio	N/A	26.39	N/A	N/A	N/A
Forward P/E Ratio	N/A	24.75	N/A	N/A	N/A
P/E Growth	N/A	2.00	N/A	N/A	N/A
Net Margins	-29.53%	5.37%	-506.70%	N/A	N/A
Return on Equity (ROE)	-3.75%	23.70%	-52.32%	-40.84%	-46.31%
Return on Assets (ROA)	-3.53%	5.99%	-33.21%	-38.33%	-45.08%
Dividend
Annual Payout	N/A	$0.48	N/A	N/A	N/A
Dividend Yield	N/A	1.72%	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	20.00%	N/A	N/A	N/A
Payout Ratio	N/A	44.44%	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	1 Years	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	1.97%	0.06%	N/A	N/A
Current Ratio	18.08%	2.88%	11.21%	24.81%	66.75%
Quick Ratio	18.08%	1.61%	11.21%	24.81%	66.75%
Ownership Information
Institutional Ownership Percentage	90.78%	50.32%	74.33%	83.49%	63.37%
Insider Ownership Percentage	10.93%	50.05%	12.60%	7.09%	N/A
Miscellaneous
Employees	141	1,700	118	21	25
Shares Outstanding	20.20 million	40.50 million	26.32 million	34.83 million	33.78 million
Next Earnings Date	8/3/2021 (Estimated)	8/25/2021 (Estimated)	8/9/2021 (Estimated)	8/11/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	ESSA Pharma (NASDAQ:EPIX) Shares Gap Up to $27.15 americanbankingnews.com - May 17 at 11:00 AM
	Brokerages Expect ESSA Pharma Inc. (NASDAQ:EPIX) to Post -$0.23 Earnings Per Share americanbankingnews.com - May 9 at 1:05 AM
	ESSA Pharma (NASDAQ:EPIX) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS americanbankingnews.com - May 8 at 10:06 PM
	ESSA Pharma reports Q1 results seekingalpha.com - May 7 at 3:05 PM
	ESSA Pharma: Fiscal Q2 Earnings Snapshot apnews.com - May 6 at 8:08 AM
	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 finance.yahoo.com - May 6 at 8:08 AM
	ESSA Pharma (NASDAQ:EPIX) Shares Gap Down to $30.24 americanbankingnews.com - May 3 at 1:36 PM
	ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference finance.yahoo.com - April 14 at 10:54 AM
	ESSA Pharma Inc (EPIX) investing.com - April 12 at 12:07 AM
	ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting finance.yahoo.com - April 10 at 12:55 PM
	ESSA Pharma to Present at Upcoming March Investor Conferences apnews.com - February 25 at 7:31 PM
	ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer finance.yahoo.com - February 25 at 9:30 AM
	ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock stockhouse.com - February 22 at 2:32 PM
	EPIX: Encouraging Initial Clinical Data for EPI-7386… finance.yahoo.com - February 12 at 3:10 PM
	HC Wainwright & Co. Maintains Buy on ESSA Pharma, Raises Price Target to $36 benzinga.com - February 12 at 12:13 AM
	ESSA Pharma's Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study finance.yahoo.com - February 11 at 2:12 PM
	Why ESSA Pharma, AnaptysBio And More Are Moving Today benzinga.com - February 11 at 12:51 PM
	Statement by the Prime Minister on the death of Christopher Plummer finance.yahoo.com - February 5 at 6:11 PM
	ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer finance.yahoo.com - January 13 at 9:15 AM
	Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative \| Morningstar morningstar.com - January 12 at 3:06 PM
	Pfizer Invests $120 Million in Biotechnology Innovation Through Pfizer Breakthrough Growth Initiative miragenews.com - January 12 at 3:06 PM
	Media Advisory - Aviation Expert Lawyer Rod Winsor Available to Answer Compensation Questions for Families of Ukraine International Airline Victims finance.yahoo.com - January 8 at 3:50 PM
	EPIX: Clinical Data for EPI-7386 in 2021… finance.yahoo.com - December 17 at 2:25 PM
	Is EPIX A Good Stock To Buy Now? finance.yahoo.com - December 15 at 11:23 PM
	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020 finance.yahoo.com - December 15 at 6:23 PM

Date	Company	Brokerage	Action
2/9/2021	Enanta Pharmaceuticals	Royal Bank of Canada	Boost Price Target
1/29/2021	Enanta Pharmaceuticals	JPMorgan Chase & Co.	Upgrade
11/23/2020	Enanta Pharmaceuticals	Evercore ISI	Initiated Coverage
10/26/2020	Enanta Pharmaceuticals	Roth Capital	Boost Price Target
9/23/2020	Enanta Pharmaceuticals	Oppenheimer	Reiterated Rating
8/25/2020	Enanta Pharmaceuticals	Piper Sandler	Initiated Coverage
7/27/2020	Enanta Pharmaceuticals	JMP Securities	Upgrade
3/17/2020	Enanta Pharmaceuticals	Robert W. Baird	Upgrade
9/18/2019	Enanta Pharmaceuticals	Berenberg Bank	Set Price Target
5/24/2019	Enanta Pharmaceuticals	Wolfe Research	Initiated Coverage
8/8/2018	Enanta Pharmaceuticals	UBS Group	Downgrade
5/13/2021	Phibro Animal Health	Morgan Stanley	Boost Price Target
5/8/2020	Phibro Animal Health	Credit Suisse Group	Lower Price Target
3/31/2020	Phibro Animal Health	G.Research	Upgrade
2/6/2020	Phibro Animal Health	Gabelli	Downgrade
1/28/2020	Phibro Animal Health	Barclays	Upgrade
8/29/2019	Phibro Animal Health	Bank of America	Lower Price Target
5/23/2019	Phibro Animal Health	Guggenheim	Initiated Coverage
5/12/2021	Arcturus Therapeutics	B. Riley	Reiterated Rating
1/7/2021	Arcturus Therapeutics	Wells Fargo & Company	Initiated Coverage
12/29/2020	Arcturus Therapeutics	HC Wainwright	Downgrade
12/29/2020	Arcturus Therapeutics	Raymond James	Downgrade
12/14/2020	Arcturus Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/14/2020	Arcturus Therapeutics	Smith Barney Citigroup	Boost Price Target
8/11/2020	Arcturus Therapeutics	Brookline Capital Management	Reiterated Rating
3/24/2021	Akero Therapeutics	Canaccord Genuity	Lower Price Target
3/23/2021	Akero Therapeutics	Jefferies Financial Group	Reiterated Rating
3/23/2021	Akero Therapeutics	Chardan Capital	Boost Price Target
2/12/2021	ESSA Pharma	Bloom Burton	Reiterated Rating

(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources